StreetInsider.com News Articles

Moss Genomics Inc. Provides Default Status Disclosure and Update on Continuous Disclosure Review

Tue, 25 Aug 2026 09:22:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - As a result of a review by the British Columbia Securities Commission (the "BCSC"), Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company") is issuing the following news release to clarify its disclosure.

The Company advises that, on July 14, 2026, it was added to the BCSC's Issuers in Default list under Canadian Securities Administrators Notice 51-322 - Reporting Issuer Defaults. The default arises from comments raised by BCSC staff in the course of a continuous disclosure review indicating that the Company's management's discussion and analysis (the "MD&A") for the

Moss Genomics Inc. Provides Default Status Disclosure and Update on Continuous Disclosure Review

Tue, 25 Aug 2026 09:22:00 -0400

Moss Genomics Reports Bitcoin Cash (BCH) Mining Activity

Mon, 05 Jan 2026 09:29:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - January 5, 2026) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") has announced it has mined a block on the Bitcoin Cash ("BCH") blockchain using proprietary mining infrastructure operated by the Company. BCH block #931,986 was mined on Jan 1, 2026 with miner ID "MOSS" included in the coinbase signature.

This mining activity represents the Company's first operation in the Bitcoin ecosystem. As a team with founding experience at several well-known products in the Bitcoin ecosystem including Ordswap, RelayX, and Bamk, this milestone advances the Company's goal to become a

Moss Genomics Reports Bitcoin Cash (BCH) Mining Activity

Mon, 05 Jan 2026 09:29:00 -0400

Moss Genomics Announces Closing of Financing Round

Wed, 12 Nov 2025 19:01:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") announces that, effective as of November 11, 2025, it has closed a non-brokered private placement of 555,555 common shares at $0.18 per share for gross proceeds of $100,000. No finder's fees were paid. Net proceeds will be used for general working capital.

In addition, effective as of November 11, 2025, Moss issued an aggregate 5,164,213 common shares at a deemed price of $0.18 per share as consideration under asset purchase agreements entered into between May 13, 2025 and July 14, 2025,

Moss Genomics Announces Closing of Financing Round

Wed, 12 Nov 2025 19:01:00 -0400

Moss Genomics Advances Blockchain Integration Strategy

Thu, 10 Jul 2025 19:33:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is providing an update on its Ethereum (ETH) Treasury Strategy. As part of this strategy, the Company has contributed 200 ETH with a commitment to contribute an additional 800 ETH to the presale of STRAT, an on-chain smart contract that enables ETH-based capital flows through algorithmic expansion and redemption mechanisms.

This contribution complements Moss's broader vision of incorporating blockchain infrastructure to support secure genomic data management. As previously disclosed on June 19, 2025, Moss entered into a non-binding term sheet for a

Moss Genomics Advances Blockchain Integration Strategy

Thu, 10 Jul 2025 19:33:00 -0400

Moss Genomics Announces Strategic Investment in Genomes.io

Thu, 19 Jun 2025 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 19, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce that on June 18, 2025, it has entered into a non-binding term sheet for a strategic, non-controlling equity investment in Genomes.io Ltd. ("Genomes.io"), a UK-based company focused on secure, user-owned genomic data storage leveraging blockchain infrastructure.

Under the terms of the proposed investment, Moss would acquire a non-controlling equity interest in Genomes.io in exchange for 1,111,112 common shares of Moss, priced at $0.18 CAD per share (the "Moss Consideration Shares"). In connection with the investment, Moss

Moss Genomics Announces Strategic Investment in Genomes.io

Thu, 19 Jun 2025 08:00:00 -0400

Moss Genomics Launches "Perennial" Genomics Platform, Closes on 130 ETH

Mon, 28 Apr 2025 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 28, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce the public launch of its genomics platform "Perennial", and closing on 130 ETH as part of its ongoing private placement.

Public Launch of Perennial

Moss is pleased to announce the public launch of its new genomics platform, "Perennial". The platform allows users to upload standard blood test results and receive deep insights personalized to their own biomarkers. Perennial, which had been in beta testing since March, represents the Company's next step toward unlocking consumer-facing, data-driven health

Moss Genomics Launches "Perennial" Genomics Platform, Closes on 130 ETH

Mon, 28 Apr 2025 07:00:00 -0400

Public Launch of Perennial

Moss Genomics Announces Listing on the OTC Markets

Fri, 11 Apr 2025 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 11, 2025) - Moss Genomics Inc. (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) (the "Company" or "Moss") is pleased to announce that its common shares are now listed for trading on the OTC Markets under the ticker MSSGF. This milestone significantly expands Moss's accessibility for U.S.-based investors and enhances overall share liquidity by enabling trading through U.S. broker-dealers.

The listing on the OTC Markets is part of Moss's broader strategy to align with global capital markets while increasing visibility and participation from the international investment community.

Moss Genomics is a biotechnology company developing next-generation genomics products that

Moss Genomics Announces Listing on the OTC Markets

Fri, 11 Apr 2025 07:00:00 -0400

The listing on the OTC Markets is part of Moss's broader strategy to align with global capital markets while increasing visibility and participation from the international investment community.

Moss Genomics is a biotechnology company developing next-generation genomics products that